Roche and Merck & Co link to develop companion diagnostic for latter's investigational cancer drugs

9 June 2011

In a further collaboration between the companies, US drugs giant Merck & Co (NYSE:MRK) has entered into an agreement with Swiss pharma and diagnostics major Roche (SIX: ROG) focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio. The companies did not disclose financial terms of the accord.

Just last month, Roche and Merck – which are rivals in the hepatitis C therapy market - announced a link up on the promotion of the latter’s newly-approved Victrelis (boceprevir) to physicians as part of a triple combination treatment regimen (The Pharma Letter May 18).

Utilizing Roche’s leadership in personalized medicines

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK